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Abstract 
Background It is believed that muscarinic M1/4 receptors are closely correlated to the dopaminergic 
system and are strongly involved in the pathogenesis of Parkinson's disease (PD). In addition to 
regulating lipid metabolism and protection from stroke, statins have been used to regulate the declined 
cognition. We aimed to explore the regional changes in M1/4 receptors in the 6-hydroxydopamine 
(6-OHDA)-lesioned rat brain. Methods PD rat model was set up by injecting 6-OHDA into the unilateral 
medial forebrain bundle; while simvastatin (10 mg/kg/day) or saline was orally administrated for 3 weeks, 
respectively. Long-term memory was measured using the Morris water maze. [3H]pirenzepine binding 
autoradiography was applied to investigate the alterations of M1/4 receptors in the PD rat brains. Results 
6-OHDA induced long-term memory deficits along with downregulation of M1/4 receptors in the 
hippocampus, the medial amygdala, the posteromedial cortical and the piriform cortex; simvastatin 
administration significantly ameliorated the impaired memory and reversed the downregulation of M1/4 
receptors in the examined brain regions. Profound positive correlations were verified between the decline 
in long-term memory activity and the restoration of M1/4 receptors in different brain regions after 
simvastatin treatment. Conclusions/significance Our results provide strong evidence that M1/4 receptor 
modulation after simvastatin administration did, at least partially, contribute to the improvement in the 
long-term memory in 6-OHDA-induced PD rats. These results provide a possible mechanism for 
simvastatin treatment in psycho-neurological diseases such as PD via M1/4 receptors. 
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Abstract 
BACKGROUND: It is believed that muscarinic M1/4 receptors is closely correlated 
to the dopaminergic system and are strongly involved in the pathogenesis of 
Parkinson’s disease (PD). In addition to regulating lipid metabolism and protection 
from stroke, statins have been used to regulate the declined cognition. We aimed to 
explore the regional changes in M1/4 receptors in the 6-hydroxydopamine (6-
OHDA) lesioned rat brain. METHODS: PD rat model was set up by injecting 6-
OHDA into the unilateral medial forebrain bundle; while simvastatin (10mg/kg/day) 
or saline was orally administrated for three weeks, respectively. Long-term memory 
was measured using the Morris water maze. [3H]pirenzepine binding 
autoradiography was applied to investigate the alterations of M1/4 receptors in the 
PD rat brains. RESULTS: The 6-OHDA induced long-term memory deficits along 
with downregulation of M1/4 receptors in the hippocampus, the medial amygdala, 
the posteromedial cortical and the piriform cortex; simvastatin administration 
significantly ameliorated the impaired memory and reversed the downregulation of 
M1/4 receptors in the examined brain regions. Profound positive correlations were 
verified between the decline in long-term memory activity and the restoration of 
M1/4 receptors in different brain regions after simvastatin treatment. 
CONCLUSIONS/SIGNIFICANCE: Our results provide strong evidence that M1/4 
receptor modulation after simvastatin administration did, at least partially, contribute 
to the improvement in the long-term memory in 6-OHDA induced PD rats. These 
results provide a possible mechanism for simvastatin treatment in psycho-
neurological diseases such as PD via M1/4 receptors. 
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Highlights: 
• 6-OHDA resulted in the impaired long-term memory in PD rats. 
• Simvastatin ameliorated the impaired long-term memory in PD rats. 
• 6-OHDA decreased M1/4 receptor binding in Hip, Me, PMCo, and Pir of PD 
rat brains. 
• Simvastatin reversed M1/4 receptor binding in the examined brain regions. 
• The altered M1/4 receptor binding was related to the long-term memory in PD 
rats. 
 
 
 
 
  
Abbreviations: 
ABC, avidin-biotin-peroxidase complex staining system; 
Acb, accumbens nucleus; 
AD, Alzheimer’s disease; 
AI, agranular insular cortex; 
Amy, amygdala; 
ANOVA, analysis of variance; 
AP: anteroposterior; 
Arc, arcuate hypothalamic nucleus; 
CA1: Cornu Ammonis area 1 
Cg, cingulate cortex; 
CPu, caudate putamen; 
DAB, diaminobenzidine; 
DMH, dorsomedial hypothalamic nucleus; 
DPX, Di-N-Butyle Phthalate in Xylene; 
DV, dorsoventral; 
Ent, entorhinal cortex; 
GPCR, G-protein-coupled receptors; 
HEPES, 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; 
Hip, hippocampus; 
HMG-CoA, hydroxymethylglutaryl-coenzyme A; 
LDL, low-density lipoprotein; 
LTP, long-term potentiation; 
M1, primary motor cortex; 
M1/4 receptor, muscarinic1/4 receptor; 
Me, medial amygdala; 
MFB, medial forebrain bundle; 
ML, mediolateral; 
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 
MWM, morris water maze; 
NMDA, N-methyl-D-aspartic acid; 
PBS, phosphate buffered saline; 
Pir, piriform cortex; 
PD, Parkinson’s disease; 
PMCo, posteromedial cortical amygdala; 
PRh, perirhinal cortex; 
RSG, retrosplenial granular cortex; 
SNpc, compact part of substantia nigra; 
SNr, reticular part of substantia nigra; 
TH, tyrosine hydroxylase; 
Tha, thalamus; 
Tu, olfactory tubercle ; 
VDB, vertical limb of the diagonal band; 
VMH, ventromedial hypothalamus; 
VTA, ventral tegmental area; 
6-OHDA, 6-hydroxydopamine. 
  
Introduction 
The cholinergic system and its neurodegeneration associated with Neurodegenerative 
diseases such as Parkinson’s diseases (PD) and Alzheimer’s disease (AD) have 
obtained considerable attention. Muscarinic receptors, one of the important elements 
in the cholinergic system, have been widely explored. Muscarinic receptors are G-
protein-coupled receptors (GPCR) that include five subtypes M1–M5 (Bymaster et 
al., 2003). Among these five subtypes, muscarinic M1 receptors that are localized to 
the postsynaptic membrane are the most studied and abundant in the cerebral cortex, 
the amygdala, the caudate putamen, and the hippocampus (Wang et al., 2008). 
Increasing evidence indicates important roles for M1 receptors in learning and 
functional memory regulation among the various neuropsychological disorders (Auld 
et al., 2002; Hu et al., 2008; Digby et al., 2012). In aged rats with a decline in 
memory and adult-onset cognitive dysfunction, the densities of M1 and M4 receptors 
were profoundly decreased in brain regions including the Cornu Ammonis area 1 
(CA1) and the frontal and occipital cortices (Tayebati et al., 2006). In Alzheimer’s 
and Parkinson’s disease patients with impaired cognitive function, the expression of 
muscarinic receptors was found to be decreased in the brain (Rodriguez-Puertas et 
al., 1997; Araki et al., 2000). 
 
Statins, hydroxymethylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, were 
normally recognized to lower plasma cholesterol. In addition to lowering cholesterol, 
statins have gradually been used to reduce the risk of heart attack, cerebral ischemia, 
and have been demonstrated to exert potential beneficial effects in different 
neurological diseases (Wang et al., 2007; Keener & Sanossian, 2008; van der Most et 
al., 2009; Sugawara et al., 2011; Ayer et al., 2013). Although the precise 
mechanisms are unclear and contrasting results have been observed (Reiss & 
Wirkowski, 2007; Becker et al., 2008), additional studies have found that statins 
display important effects on cognitive related neurological diseases such as PD (Wu 
et al., 2008; van der Most et al., 2009; Wang et al., 2011; Lee et al., 2013; Xu et al., 
2013). If statins would have a potentially useful impact on impaired memory 
regulation in the progression of PD, this presents an interesting challenge. Besides 
characterized by typical disturbances of dopaminergic system, PD patients also 
display widely unbalances in other systems including cholinergic system (Gubellini 
et al., 2004; Lester et al., 2010; Xu et al., 2012). It has been indicated that the 
interruption of dopaminergic system may influence the cholinergic system in PD 
(Andersson et al., 2010; Lester et al., 2010). Our studies and Selley (Selley, 2005; 
Wang et al., 2005) have shown that simvastatin regulated dopaminergic systems 
including receptors and transmission in the brain. Also, our study found the alterations 
of NMDA and M1/4 receptors in the brains following simvastatin treatment (Wang et 
al., 2008; Wang et al., 2009b; Yan et al., 2011). Whether the application of simvastatin 
in Parkinsonian rats also influences the expression of M1 receptors raises an interesting 
question.  
 
Based on the information above, we propose that simvastatin may reverse the decline 
in M1/4 receptors in memory-related regions of the brain in 6-OHDA-induced PD 
rats. To test this hypothesis, [3H]pirenzepine binding autoradiography was applied to 
verify the reactions of muscarinic receptors M1/4 to 3-week treatment of simvastatin 
in the 6-OHDA-induced PD rat model. Besides, we also investigated the impairment 
of memory in this PD rat model, as well as the influence of simvastatin on declined 
memory in the PD rat model. The current study provides a possible association of 
simvastatin treatment with M1/4 receptors in the Parkinsonian rat brain. 
 
Materials & Methods 
Animals and drug treatments 
Twenty-two Sprague-Dawley rats (male, 230-250 g/rat) were purchased from the 
Animal Resources Centre (Perth, Western Australia, Australia) and kept in 
specifically environmental conditions as previous description (Li et al., 2010). Rats 
were housed for one week to be accustomed to the new environment before 
experiments start. The rats were randomly assigned to groups with a total of sixteen 
rats for the 6-OHDA lesioned group, among which eight of the rats were 
administered with simvastatin (10 mg/kg/day) orally and the rest rats were orally 
administrated with saline. One 6-OHDA lesioned rat receiving saline died after 
surgery. In the control group, six rats received 0.9% saline for three-week oral 
administration as the vehicle control. After three weeks of 6-OHDA lesion, all rats 
were sacrificed to examine M1/4 receptor binding. This study was approved by the 
local Animal Ethics Committee, and followed the instructions in compliance with the 
National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH 
Publications No. 80-23) revised 1996 guidelines and National Health and Medical 
Research Council (NHMRC) Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (2004). 
 
6-OHDA lesioned Parkinsonian rats 
The 6-OHDA lesioned rat was created as described in Yan’s work (Yan et al., 2011). 
Briefly, the rats were anesthetized with 75 mg/kg ketamine and 10 mg/kg xylazine 
(Troy laboratories Pty, Ltd., Australia). 4 μl 6-OHDA was diluted in the normal 
saline (8 μg/μl in normal saline containing 0.2 mg/ml ascorbic acid, Sigma-Aldrich, 
St. Louis, MO) were unilaterally injected into the medial forebrain bundle (0.8 
μl/min; at AP −4.4 mm, ML −1.4 mm and DV −7.8 mm, from Bregma (Paxinos & 
Watson, 1997). The control group were orally administrated with the 0.9% saline 
vehicle, and received the 0.9% saline injection into the MFB. These animal 
procedures were conducted according to the protocols set up by the University of 
Wollongong, adapted from Howard-Jones (Howard-Jones, 1985). 
 
Morris water maze (MWM) 
Three weeks after the 6-OHDA lesion was performed, rats were tested in the MWM 
to assess the level of long-term memory. The MWM was described in previous 
studies (Andringa et al., 2000; Wisman et al., 2008). Briefly, the pool dimensions 
were a diameter of 185 cm and a water depth of 30 cm, and the water temperature 
was 21° Celsius. A hard plastic circular cover that fits inside the wall of pool was 
used as a protective sheath so that the rats would not scratch the rubber pool material. 
Four starting positions were conventionally indicating east, south, west, and north, 
which divided the pool into 4 quadrants. A target platform (10 x 10 cm) was placed 
midway between the center and the western point. The platform consisted 
of transparent plexiglass and was submerged 1.5 cm beneath the surface 
of the water. Rats were tested 2 days in succession, with two training 
trials conducted in the first day for the learning phase. On the second 
day, the test trial was performed to test the long-term memory. The 
distance that the rat travelled and the time that the rat took to reach the 
platform was recorded by a camera placed 2 meters above the water 
maze. Distance and duration was traced and calculated using Ethovision 
Color-Pro software (Nldus information Technology, Wageningen, The 
Netherlands). 
 
Tyrosine hydroxylase immunohistochemistry staining 
After the MWM behavioral test, the rats were used for tyrosine 
hydroxylase (TH) staining. TH staining was performed as described in 
Yuan’s study (Yuan et al., 2005; Yan et al., 2011). Briefly, distilled 
water was used to wash the brain sections for three times (5 min/per 
time), and the sections were immerged in citrate buffer for 20 minutes. 
1.5% goat serum was used to block the non-specific binding (Vectastain 
rabbit IgG ABC kit). The sections were incubated with TH primary 
antibody (rabbit polyclonal anti-tyrosine hydroxylase, Millipore 
Corporation, AB152) overnight at 4 °C. On the following day, the 
sections were incubated with the secondary antibody for 60 min 
followed by PBS wash. After ABC (Vectastain rabbit IgG ABC kit) and 
DAB kits were applied (DAB, Vector SK-4100), the sections were 
determined by light microscopy. The TH staining density was detected 
by the NIH ImageJ Analysis software. 
 
Histology and [3H]pirenzepine binding autoradiography 
CO2 asphyxiation was used to kill the rats. Microscope slides (Polysine™, Menzel 
GmbH & Co KG) were mounted with the brain sections cut at 14 μm thickness (Li et 
al., 2010; Yan et al., 2011). Rat brain atlas was used to identify standard brain 
structures (Paxinos & Watson, 1997). [3H]Pirenzepine autoradiography was 
performed to detect the M1/4 receptor binding (Newell, 2007; Wang et al., 2008). 
Briefly, brain sections were incubated in HEPES (pH 7.5) for 15 minutes, and then in 
the same buffer but adding 10 nM [3H]pirenzipine (specific activity 86 Ci/mmol; 
Perkin Elmer, Norwalk, CT) for 90 minutes. Nonspecific binding was identified with 
[3H]pirenzepine in the presence of 10 μM atropine. 
 
Quantification and Statistical Analysis 
Beta Imager (BioSpace, Paris, France) was applied to quantify the M1/4 receptor 
binding sites as described in our previous studies (Wang et al., 2009b; Yan et al., 
2011). Briefly, brain sections were put in the chamber of Beta Imager followed by 
3.5 h scanning. By quantifying the _-particles emitting from the brain sections, the 
levels of radioactivity in the tissue were directly determined; while the Beta Vision 
Plus program (BioSpace) was used to measure the activities in the interested regions. 
The radioligand binding signal was expressed in counts per minute per square 
millimeter (cpm/mm2). The radioligand binding signals was converted to nCi/mg 
tissue equivalents. Three to five adjacent brain sections were used to quantify the 
average density of M1/4 receptor by measuring [3H]pirenzepine binding in various 
brain regions. Data were expressed as the mean ± SEM. [3H]Pirenzepine binding 
densities for each brain region, and the behavioral data from the MWM were 
analysed using a one-way ANOVA followed by a post hoc Dunnett-T test with the 
SPSS 15.0 program (Chicago, IL). A Student’s t-test was employed to analyze the 
data from the TH immunohistochemistry staining in Cpu. P values of less than 0.05 
were regarded as statistically significant. 
 
Results 
TH immunostaining in the striatum 
In the Striatum: TH immunoreactivity showed that the lesion by 6-OHDA into the 
MFB induced an extent nigrostriatal denervation in the striatum (Fig. 1). Fig. 1B 
showed a large absence of TH immunoreactive fibers, and the average density of TH 
immunoreactivity was expressed as a mean percentage ± S.E.M. The density of TH-
positive fibers in the lesioned side was reduced around 80% when compared to the 
controls (Student t-test: t=18.551, *** p< 0.001, Fig. 1C). In the 6-OHDA lesioned 
rat, the TH density in the intact side of striatum was the same as that of control group 
(Fig. 1A). 
 
Effects of 6-OHDA lesion and simvastatin treatment on long-term memory 
One-way ANOVA demonstrated that there was a significant effect of drug treatment 
on the total distance traveled in the MWM (F[2,18] =4.340, p=0.029, Fig. 2A). 
Compared to the controls, 6-OHDA caused a significant increase in the total distance 
(235% of controls, p<0.05) (Fig. 2A). When compared to the 6-OHDA treated group, 
simvastatin significantly prevented this increase in the total distance (41.4% of 6 
OHDA group, p<0.05). In addition, one-way ANOVA demonstrated that there was a 
significant effect of drug treatment on the ratio of the duration in the west arena to 
the total duration (F[2,18] =4.353, p=0.029). A post hoc test indicated that 6-OHDA-
lesion PD rats showed a significant decrease (27%, p<0.05) in the ratio of the 
duration in the west arena to the total duration compared to controls (Fig. 2B). In 
comparison to the 6-OHDA-lesion PD rats, simvastatin oral administration 
significantly prevented this behavioral deficit in which simvastatin treated PD-rats 
had a significantly longer duration in the west arena (36%, p<0.05, Fig. 2B). 
 
Effects of 6-OHDA lesion and simvastatin treatment on [3H]pirenzepine 
bindingin the brain regions 
[3H]pirenzepine binding sites can be found in most examined areas (Fig. 3). One way 
ANOVA revealed significant changes in [3H]pirenzepine binding sites in some 
examined brain regions such as hippocampus, the medial amygdala, the posteromedial 
cortical amygdale, and the piriform cortex among the 6-OHDA induced PD rats. 
Specifically, a Tukey post-hoc analysis showed that [3H]pirenzepine binding in 6-
OHDA-lesioned rats was profoundly reduced in the hippocampus (9.34%, p<0.01), the 
medial amygdala (11.91%, p<0.01), the posteromedial cortical amygdala (12%, p<0.05) 
and the piriform cortex (13.60%, p<0.01) compared to the controls (Figs 4 and 5). 
However, after three-weeks of administration of simvastatin, the down-regulation of 
[3H]pirenzepine binding sites in these examined regions were reversed. Specifically, 
simvastatin significantly increased the [3H]pirenzepine binding density in the 
hippocampus (11.4%, p<0.01), the medial amygdala (11.38%, p<0.05), the 
posteromedial cortical amygdala (12.45%, p=0.064) and the piriform cortex (15.23%, 
p<0.001) in comparison to the 6-OHDA MFB lesioned PD rats (Figs 4 and 5). 
However, compared to the controls, no significant changes in [3H]pirenzepine binding 
were observed in the substantia nigra of the 6-OHDA and simvastatin treated group. In 
the caudate putamen (11.07%, p=0.001), [3H]pirenzepine binding was significantly 
increased in the simvastatin treated group in comparison to the 6-OHDA and control 
groups. 
Correlations between duration in west arena of MWM and [3H]pirenzepine 
binding density 
A moderate positive correlation was observed between the [3H]pirenzepine binding 
density in the hippocampus and the duration in the west arena of the water maze 
(r=0.491 Pearson’s correlation, p=0.024) in the MWM test (Fig 6A). There were also 
significant correlations between the [3H]pirenzepine binding density in the medial 
amygdala (r=0.636, p=0.002) with the duration in the west arena of the water maze 
(Fig 6B) in the MWM test. However, no significant correlation was observed 
between [3H]pirenzepine binding density in the posteromedial cortical amygdala 
(r=0.148, p=0.520) or the piriform cortex (r=0.315, p=0.164) and the duration in the 
west arena of the MWM. 
 
Discussion 
The current study was to explore the changes of [3H]pirenzepine binding density in 
6-OHDA lesioned rat brain regions and its association with memory activity after 
chronic treatment of simvastatin. Although [3H]pirenzepine possess the higher 
concentration, [3H]pirenzepine binds largely to the M1 receptor subtype (Dean et al., 
1999). The present study used 10 nM [3H]pirenzepine, a concentration that was 
reported to label approximately 65% of M1 receptors and 18.5% of M4 receptors 
(Flynn & Mash, 1993). The current study showed that compared with control group, 
the 6-OHDA lesion significantly decreased M1/4 receptor binding in some brain 
areas such as the hippocampus, the medial amygdala, the posteromedial cortical 
amygdala and the piriform cortex. 
 
In this study, the profoundly reduced TH immunostaining in the striatum of the 6-
OHDA-lesioned side indicated a complete nerve terminal denervation and successful 
6-OHDA induced PD rat model establishment. In the MWM, 6-OHDA lesioned rats 
travelled a longer distance and used more time to reach to the target platform 
compared to the controls (Fig 2), reflecting the effects of the 6-OHDA lesions, which 
induce a decline in long-term memory. Our result is similar to other studies, which 
indicated that 6-OHDA or MPTP lesioned PD rodents showed severely impaired 
long-term memory activity (Da Cunha et al., 2002; Yang et al., 2004). Clinical 
studies showed that before the motor feature deficits showed up, PD patients usually 
present nonmotor dysfunctions, especially, the neuropsychiatric dysfunctions, among 
which memory impairment is a typically characteristic; in this case, the prevalence 
rates were up to 67% in the PD population (Emre et al., 2007). For example, in some 
cross-sectional clinical cohort studies, it has been shown that PD patients exhibited 
memory deterioration in the early stage and gradually developed progressive 
memory decline; while this memory impairment was improved by different medical 
interventions (Uc et al., 2009; Wang et al., 2009a; Caviness et al., 2011), the precise 
mechanisms are not yet clear. Therefore, it is urgently to investigate the possible 
mechanisms on the memory impairment in PD; this study directly implies this 
cognitive profile in clinical PD patients. 
 
Our study showed that a 6-OHDA lesion in the MFB induced a reduction of M1/4 
receptor binding in the observed brain regions (Figs 4 and 5). This finding is 
consistent with other studies demonstrating that M1/4 receptors were decreased in 
the brain following 6-OHDA induced dopaminergic depletion (Joyce, 1991a; b). The 
precise reasons for the reduced M1/4 receptor following a 6-OHDA lesion are not yet 
known. However, it has been documented that dopaminergic denervation in the 
striatal pathway resulted in hyperactivity of the cholinergic systems (Muma et al., 
2001; Zhang et al., 2008). Therefore, we hypothesize that the possible mechanisms 
for the reduced M1/4 receptors involved in our study is due to enhanced striatal 
cholinergic neuron firing following dopamine denervation in the nigrostriatal 
pathway; however, we cannot exclude the possibility that the reduced M1/4 receptors 
in the observed brain areas may reflect the receptor hypo-innervations. However, the 
precisemechanisms behind it remain to be determined. 
 
It has been well documented that the changes of M1/4 receptors in the some brain 
regions are closely correlated with the memory activity. A recent study by 
Anagnostaras et al. indicated that through Olton win-shift radial arm maze and 
morris water maze studies, M1 receptor knockout mice showed dramatic 
forgetfulness and impaired working and contextual memory, implying that the 
function of the M1 receptor directly contributes to memory processing (Anagnostaras 
et al., 2003). By inhibiting M1 receptors using its antagonist pirenzipine, the long-
term potentiation (LTP) induction that serves as a cellular mechanism for memory 
was abolished, strongly suggesting that M1 receptors mediate memory and learning 
function (Doralp & Leung, 2008). Although some early studies showed no 
significant decrease in M1 receptor expression in the brains of declined memory 
related disorders (Young & Penney, 1994), more recent studies showed that M1 
receptor levels were significantly declined in some important brain regions, such as 
the cortex and the hippocampus, among the many memory impairment related 
disorders (Parasi et al., 2007). Further, the declined memory in aged rats can be 
improved by elevating the expression of M1 receptors in memory related brain 
regions, such as the hippocampus and the cortex (Hu et al., 2005; Hu et al., 2008). 
This study showed that a profound decrease in the M1/4 receptor binding was 
observed in the hippocampus, the medial amygdala, the posteromedial cortical, and 
the piriform cortex of the 6-OHDA lesioned side. This robust decrease of M1/4 
receptor binding in the hippocampus and medial amygdala, of 6-OHDA lesioned rats 
was found to have significant positive correlations with the duration in the west arena 
of the water maze in the MWM test (Figs 6A and 6B). These findings strongly 
suggest that the M1/4 receptor hypofunction in the hippocampus and medial 
amygdale may explain the declined memory in the PD rats. This hypothesis is 
supported by the fact that the changes in the M1/4 receptors in the examined regions 
directly regulate the memory behaviors. 
 
Similar to previous reports (Rezvani et al., 2008), 6-OHDA lesioned rats in the 
current study showed deficits in long-term memory as indicated by the longer total 
distance travelled to reach the platform and the shorter duration in the west arena of 
the water maze. It is important that simvastatin treatment significantly increased the 
reduced total distance travelled in the MWM and the duration of the 6-OHDA-
induced PD rats in the west arena of the water maze (Fig 2), demonstrating the 
ability of simvastatin to produce a profound improvement in impaired memory 
effects in the 6-OHDA lesioned PD rats. Consistent with our results, through 
behavioral tests, Chopp’s team and others also found that simvastatin substantially 
improved deficit spatial learning and memory in an established mouse model of AD 
and rats subjected to traumatic brain injury (Li et al., 2006; Lu et al., 2007; Wu et al., 
2008). An increasing number of clinical studies have indicated close association 
between statins and improvement in declined memory in the elderly population. In a 
follow-up cohort investigation, Solomon et al. demonstrated that subjects with 
pronounced impairment in episodic memory benefited from statins usage, implying 
that statins exert useful impacts on memory deficits in the elderly (Solomon et al., 
2009). Several prospective studies showed that poorer memory performance was 
significantly ameliorated in Parkinson’s disease following statin therapy (Wahner et 
al., 2008; Mutez et al., 2009). However, the means by which statins affect memory 
and several possible mechanisms underlying memory regulation are under 
exploration. The current study showed that the reduced [3H]pirenzepine binding sites 
in the observed brain regions was reversed after chronic treatment of simvastatin, 
which is consistent with our previous study showing an increase of M1/4 receptors in 
the rat brain following simvastatin treatment (Wang et al., 2008). This result 
indicated that the increase of M1/4 receptor binding in the hippocampus and the 
medial amygdala of 6-OHDA lesioned rats after chronic treatment of simvastatin was 
identified to have significant positive correlations with the duration in the west arena 
of the MWM (Fig 6). This finding implies that simvastatin ameliorated the declined 
memory in 6-OHDA lesioned rats via M1/4 receptor modulation. 
 
In addition to the in vivo and in vitro studies, recent clinical studies indicated that 
some types of statins may be associated with a reduction in PD risk. A population-
based study by Lee et al., indicated that the continuation of lipophilic statin, such as 
atorvastatin and simvastatin, therapy was associated with a decreased incidence of 
PD (Lee et al., 2013). During 12 years of follow-up (1994-2006) study, Gao et al., 
found that the regular statin medication was correlated to a reduction in PD risk (Gao 
et al., 2012). Similar clinical meta analysis and review on the association of statin 
therapy with the decreased risk of PD was also obtained in other studies (van der 
Most et al., 2009; Dolga et al., 2011; Noyce et al., 2012). Taken together, clinical 
and epidemiological investigations provided strong evidence that statin therapy may 
be used to slow down the progression of PD patients. In conclusion, the current study 
provides the solid evidence indicating the influence of simvastatin on M1/4 receptor 
binding in the PD rat brain. It also reveals possible M1/4 receptor modulation effects, 
which indicates an interesting and potential paradigm to ameliorate memory deficits. 
According to our results, we reasonably speculate that the improvement in long-term 
memory performance due to simvastatin administration in 6-OHDA-induced rats is, 
at least partially, associated with a reversal of the declined M1/4 receptor density. 
This work presents a possible mechanism for the amelioration of memory deficits in 
PD by simvastatin, suggesting that it is mediated by M1/4 receptor modulation. 
Although the rat brain resembles the human brain to a certain degree, it does not 
mean we can directly translate the results from animal data to humans. However, this 
current animal study could provide pre-clinical evidence for clinical studies on PD. A 
better understanding of the roles and correlations between statins and dopaminergic 
and muscarinic systems may provide new perspectives on the role of statins in 
regulating neurodegenerative diseases such as PD and AD. 
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Figure legends 
 
Fig 1. Effects of 6-OHDA lesion on TH immunohistochemistry staining in the 
caudate putamen. Photo (A) represents the striatum in the control group in which the 
TH immunoreactive fibers are the same as in the intact side. The right side of the 
photo (B) shows the dopamine-depleted striatum side, which is characterized by a 
significant lack of TH immunoreactive fibers, while the left side is the intact side. 
(C) represents the average density of TH-positive fibers for the lesioned side and the 
contralateral (intact) side (Student’s t-test: t= 18.551, ***P < 0.001). 
 
Fig 2. Effects of simvastatin on the long-term memory activity of control, 6-OHDA-
lesioned, and 6-OHDA-lesioned with simvastatin administration rats in the MWM 
test. The graph shows the total distance travelled and the ratio of the duration in the 
west arena to the total duration in the MWM. The parameters are expressed as the 
total distance (A) and the percentage of time spent in the west zone to the total time 
(B) in the MWM. (A) represents the mean ±SEM, n=6-8. *p<0.05, 6-OHDA group 
versus control group; **p < 0.01, 6-OHDA + saline group versus 6-OHDA + 
simvastatin group. (B) represents the mean ±SEM, n=6-8. *p<0.05, 6-OHDA group 
versus control group; ＃ p < 0.05, 6-OHDA + saline group versus 6-OHDA + 
simvastatin group. 
 
Fig 3 The maps of A, B and C are adapted from a rat brain atlas (Paxinos & Watson, 
1997) indicating the levels where the [3H]pirenzepine binding density was measured. 
Autoradiographs (D, E, F) and (D', E', F') depict the expression of [3H]pirenzepine 
binding and non-specific [3H]pirenzepine binding, respectively, at different rostro-
caudal coronal levels of the rat brain. 
 
Fig 4 Typical autoradiographs depict the expression of M1 receptors in the 
hippocampus (Hippo) and amygdale (Amy) among the control rats, the 6-OHDA 
lesioned rats and the 6-OHDA lesioned rats with simvastatin treatment. 
 
Fig 5 The effects of chronic simvastatin treatment on [3H]pirenzepine binding in the 
different groups of rat brain regions. Note: Units of measurement are in nCi/mg 
tissue. Data are represented as the mean ± SEM. Asterisks indicate significant 
differences from the control group (saline), and the cross indicates significant 
differences between the 6-OHDA rats and the 6-OHDA with simvastatin treated rats 
(*p<0.05; †p<0.05; ††p<0.01; one-way ANOVA followed by Tukey’s test). 
 
Fig 6 Correlations between the duration in the west arena of the MWM and 
[3H]pirenzipine binding density in brain regions. A significant positive correlation 
was identified between the [3H]pirenzepine binding density in the hippocampus 
(r=0.491 Pearson’s correlation, p=0.024, Fig A), amygdala (r=0.636, p=0.002, Fig 
B), and the duration in the west arena of the MWM test. However, no significant 
correlation was observed between [3H]pirenzepine binding density in the 
posteromedial cortical amygdala (r=0.148, p=0.520), the piriform cortex (r=0.315, 
p=0.164), and the duration in the west arena of the MWM. 
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